Exploring the comparative regressive effects of aflibercept and faricimab on pigment epithelial detachment

BMC Ophthalmol. 2024 Sep 3;24(1):393. doi: 10.1186/s12886-024-03663-8.

Abstract

Background: This study aimed to compare the regressive effects of aflibercept and faricimab on pigment epithelial detachment (PED) in patients with neovascular age-related macular degeneration.

Methods: In total, 41 eyes of 40 patients diagnosed with type 1 macular neovascularization were retrospectively analyzed using multimodal imaging. Of these, 23 eyes were treated with intravitreal aflibercept injections (IVA group), and 18 eyes were treated with intravitreal faricimab (IVFa group), with 3 consecutive injections administered as loading dose therapy. Before treatment and at 1, 2, and 3 months after the first treatment, the maximum height (MH) and maximum diameter (MD) of the PED were measured using optical coherence tomography in each treatment group.

Results: In the IVA group, the MH at baseline (215 ± 177 μm) was reduced to 141 ± 150 (P = 0.06), 119 ± 150 (P < 0.01), and 107 ± 150 µm (P < 0.0001) at 1, 2, and 3 months after treatment, respectively. Similarly, in the IVFa group, the MH decreased from 240 ± 195 µm before treatment to 165 ± 170 µm (P = 0.24), 139 ± 142 µm (P < 0.05), and 117 ± 112 µm (P < 0.01) at 1, 2, and 3 months after treatment, respectively. The reduction at 2 and 3 months was significant in both treatments. The mean changes of MH from baseline were -108 ± 142 µm in the IVA group and -124 ± 112 µm in the IVFa group, with no significant difference (P = 0.21). In both groups, the MD did not regress significantly.

Conclusions: The results suggested that the MH of the PED between the IVA and IVFa groups regressed similarly after each loading therapy.

Keywords: Aflibercept; Age-related macular degeneration; Faricimab; Pigment epithelial detachment.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors* / therapeutic use
  • Female
  • Fluorescein Angiography
  • Humans
  • Intravitreal Injections*
  • Male
  • Middle Aged
  • Receptors, Vascular Endothelial Growth Factor* / antagonists & inhibitors
  • Receptors, Vascular Endothelial Growth Factor* / therapeutic use
  • Recombinant Fusion Proteins* / administration & dosage
  • Recombinant Fusion Proteins* / therapeutic use
  • Retinal Detachment* / diagnosis
  • Retinal Detachment* / drug therapy
  • Retinal Pigment Epithelium* / drug effects
  • Retinal Pigment Epithelium* / pathology
  • Retrospective Studies
  • Tomography, Optical Coherence* / methods
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity*
  • Wet Macular Degeneration / diagnosis
  • Wet Macular Degeneration / drug therapy
  • Wet Macular Degeneration / physiopathology

Substances

  • aflibercept
  • Receptors, Vascular Endothelial Growth Factor
  • Recombinant Fusion Proteins
  • Angiogenesis Inhibitors
  • Vascular Endothelial Growth Factor A